Akeso, Summit Therapeutics, ivonescimab, HARMONi-GI1, biliary tract cancer, BTC, Phase 3 clinical trial, overall survival, durvalumab, bispecific antibody, PD-1 inhibitor, VEGF inhibition

Hong Kong, China, and Madrid, Spain, October 25, 2026 Akeso, Inc., in collaboration with Summit Therapeutics, has reported positive...